Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Nebivolol 2.5 mg Tablet
Therapeutic Category
Hypertension/ Blood Pressure, Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹99/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Nebivolol 2.5 mg Tablet is a highly selective beta-1 adrenergic receptor blocker with additional nitric oxide (NO)-mediated vasodilatory properties. This dual mechanism not only reduces heart rate and myocardial oxygen demand but also promotes vasodilation, leading to effective blood pressure control and improved arterial compliance. Compared to traditional beta-blockers, Nebivolol offers better tolerability, minimal metabolic side effects, and is less likely to cause fatigue or sexual dysfunction. The 2.5 mg dose is typically used as a starting dose in elderly patients, those with mild hypertension, or in patients with reduced kidney function who require careful dose titration. In addition to treating hypertension, Nebivolol also provides cardioprotective benefits by improving endothelial function and reducing oxidative stress.
Common side effects include headache, dizziness, fatigue, and bradycardia (slow heart rate). Some patients may experience mild gastrointestinal disturbances or sleep-related issues. Rare but serious adverse effects include severe hypotension, worsening heart failure, or bronchospasm in susceptible individuals. Because of its cardioselectivity, respiratory side effects are less common compared to non-selective beta-blockers.
Nebivolol 2.5 mg Tablet is indicated for the management of essential hypertension in adults, either as monotherapy or in combination with other antihypertensive agents. It is also used in selected cases of stable heart failure with reduced ejection fraction as part of a comprehensive treatment plan.
Nebivolol 2.5 mg should be taken only under medical supervision. It is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, or severe liver impairment. Caution is advised in patients with asthma, COPD, diabetes, or thyroid disorders. The dose should not be stopped abruptly, as sudden discontinuation may cause rebound hypertension or worsening of angina. It is not recommended during pregnancy and breastfeeding unless prescribed by a physician after risk assessment. Alcohol should be minimized as it can potentiate the blood pressure-lowering effect. Regular monitoring of blood pressure, heart rate, and clinical response is recommended for safe and effective therapy.
Store Nebivolol 2.5 mg Tablet in a cool, dry place below 30°C, away from direct sunlight and moisture. Keep the tablets in their original packaging and out of the reach of children. Do not use after the expiry date printed on the pack.
Composition : Atorvastatin 10mg + Aspirin 75mg + Clopidogrel 75mg Capsule
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin (5mg) tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 20 mg + fenofibrate 160 mg tablet
Composition : Rosuvastatin 10 mg + Telmisartan 40 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Nebivolol Tablets have strong demand in the cardiology and antihypertensive segment, making them a valuable prescription product for pharma distributors, wholesalers, and franchise partners. It is widely prescribed for hypertension, cardiovascular risk reduction, and long-term heart health management, ensuring consistent repeat prescription demand.
Medical distributors and agencies benefit from the growing prevalence of hypertension and cardiovascular disorders. Helps effectively control high blood pressure Supports long-term cardiovascular protection Selective beta-blocker with favorable tolerability profile Helps reduce heart rate and cardiac workload Widely prescribed by cardiologists and general physicians Suitable for long-term daily antihypertensive therapy Strong demand in hospital, clinic, and retail pharmacy segments This makes it a high-demand cardiovascular product with excellent repeat prescription potential.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Nebivolol 2.5 mg Tablets with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from consistent cardiology prescription demand, long-term patient adherence, strong physician confidence, and stable year-round turnover in the cardiovascular segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete cardiology and antihypertensive product portfolio access to build a strong presence in the cardiovascular healthcare market.